Probabilities for a near-term, comprehensive federal rescheduling of marijuana fell sharply on Thursday, April 23, 2026, after the Department of Justice (DOJ) announced a final order that reclassified certain medical cannabis products but established a longer administrative path for broader changes. The move, which partially fulfilled a directive from President Donald Trump, prompted a significant repricing in prediction markets. The contract for rescheduling to occur "Before July 2026" experienced the most dramatic shift, plunging 27.4 percentage points as traders adjusted to the new, more defined regulatory timeline.
The repricing was not isolated to the near-term contract. Every tracked outcome in the KXMJSCHEDULE series saw its probability decline, signaling a market-wide consensus that while some form of rescheduling has occurred, a complete reclassification that includes recreational cannabis has been pushed further into the future. The high trading volume on the declining contracts suggests strong conviction behind the shift.
Distribution Analysis
The market repricing reflects a uniform pushback of the expected timeline for a comprehensive rescheduling of marijuana. The most significant drop occurred in the nearest-term contract, with successively smaller declines for later-dated outcomes.
| Outcome | Current Prob | Change | Volume |
|---|---|---|---|
| Before July 2026 | 10% | -27.4pp | 415,498 |
| Before 2027 | 48% | -16.0pp | 125,638 |
| Before 2028 | 72% | -6.0pp | 4,158 |
| Before Jan 20, 2029 | 77% | -4.0pp | 435 |
Net: 4 of 4 contracts declined on over 545,000 in total volume, shifting the implied timeline for a comprehensive rescheduling further into the future.
What's Driving the Shift
The market's sharp adjustment appears to be a direct reaction to the specifics of the Justice Department's long-awaited announcement on marijuana's status under the Controlled Substances Act (CSA).
A Partial, Not Comprehensive, Rescheduling: The DOJ order, effective April 22, 2026, reclassified two specific categories of marijuana to Schedule III: FDA-approved drug products and marijuana subject to a state-issued medical license [1, 3]. While a landmark development, the order explicitly states that any other form of marijuana—critically, including state-licensed recreational products—remains a Schedule I controlled substance [4, 5]. This fell short of the comprehensive reclassification that traders betting on near-term deadlines may have anticipated.
A New, Formal Timeline: The DOJ and Drug Enforcement Administration (DEA) also announced the start of a new, expedited administrative hearing process to consider the broader rescheduling of all marijuana from Schedule I to Schedule III [3]. This hearing is scheduled to begin on June 29, 2026 [4]. By establishing a formal, forward-looking administrative procedure, the announcement effectively ended speculation of an imminent, all-encompassing change and created a new, more concrete—and longer—timeline for traders to price. The collapse in the "Before July 2026" contract reflects the near impossibility of this new process concluding within that timeframe.
"Sell the News" Dynamic: The order delivers on a December 2025 executive order from President Trump to expedite rescheduling [2, 7]. However, the finality and limited scope of the action seem to have created a "sell the news" event. Uncertainty about the administration's move has been replaced by the reality of a partial rescheduling and a defined administrative process for anything further. This clarity, while a step forward in policy, was bearish for market contracts pricing in a faster and more sweeping outcome.
Market Context
Since the Controlled Substances Act was passed in the 1970s, marijuana has been classified as a Schedule I drug, a category for substances with no accepted medical use and a high potential for abuse, alongside heroin and LSD [6]. The move to place medical products in Schedule III, alongside substances like ketamine and Tylenol with codeine, represents a historic shift in federal drug policy [2].
For state-licensed medical marijuana businesses, the change is significant, as it will allow them to deduct standard business expenses from their federal taxes, a practice forbidden for companies trafficking in Schedule I or II substances [1, 7].
However, the prediction market's reaction underscores the crucial distinction between this specific regulatory change and the broader federal legalization or rescheduling sought by many advocates and industry participants. While the odds of a quick resolution have diminished, longer-term contracts remain priced at high probabilities, with the "Before Jan 20, 2029" contract still at 77%. This suggests the market consensus is not if a broader rescheduling will happen, but when, with expectations now aligned with a more formal and extended regulatory process.
What to Watch
The primary event for this market is now the DEA's administrative hearing process set to commence on June 29, 2026 [3]. The pace, scope, and ultimate recommendations from that hearing will be the next major catalyst for prices. The market itself is scheduled to close in early 2029 and will resolve based on reports from a slate of major news organizations.
